Pemigatinib is an FGFR inhibitor. It’s specifically designed for cholangiocarcinoma with FGFR2 fusions. The med’s all about blocking that FGFR signaling pathway.
It’s a tablet, come in 4.5 mg, 9 mg, and 13.5 mg versions. You’re supposed to take 13.5 mg of it every day for two weeks every 21-day cycle. Every pack comes with a bottle of 14 pills, which is enough for a full cycle at the advised dosage.
